Business Wire

REPLY: Politecnico di Torino And Reply Reaffirm Their Commitment to Training Tomorrow’s Digital Experts With the Second Edition of the Second-level Master's in ARTIFICIAL INTELLIGENCE & CLOUD

Share

Following the success of the first edition and the satisfaction shown by all the students who participated in the training path, and now in working in corporate projects, Reply and the Specializing Master's Programmes and Lifelong Learning School of the Politecnico di Torino announce that enrolment is now open for the second edition of the second-level Master's degree course in "Artificial Intelligence & Cloud Hands-on innovation".

Starting in January 2022, the Master’s offers 40 highly qualified students a professional specialisation path in the IT sector through its most innovative technologies: artificial intelligence, machine learning and cloud.

The lessons will be held in person at the Politecnico di Torino and will combine Politecnico di Torino professors and Reply specialists in a mix of theoretical lessons and practical live cases. During the programme, students will work in groups on live projects at Reply, where they will put into practice the knowledge acquired in the classroom.

The Master's is open to students who have previously obtained a Master's degree in either Computer Science, Computer Engineering, Automation Engineering, Telecommunications Engineering, Electronic Engineering and Cybersecurity (the degree must be completed by December 31, 2021). The entire course is in English and it is open to international entrants.

Applications should be submitted online by October 22,2021 following the instructions available at master.reply.com. This will be followed by an evaluation process in which a commission made up of members of the Politecnico di Torino and Reply professionals will assess the candidates' curricula, educational background and professional experience. The commission will also meet each candidate for an individual interview.

The “Earn While You Learn” formula has also been confirmed for this second edition. Reply commits to hire the selected candidates right from the start of the programme and to bear all the costs of participation in the Master’s for those who accept the job offer.

“Through this specialisation path, in collaboration with the Politecnico di Torino, we aim to create an elite group of students who are highly qualified in the most innovative IT issues and to progressively include these students in our projects” explains Filippo Rizzante, Reply CTO. “Artificial intelligence, machine learning and cloud are fundamental for Reply and for our customers, which is why we want to train students in these technologies right from the start.”

"The Master’s in collaboration with Reply – explains the Specializing Master's Programmes and Lifelong Learning School’s Director, Prof. Paolo Neirotti – is one of the initiatives of excellence that the Master’s School designs and delivers. The programme has a custom-made approach for sector leaders and confirms that the digital transformation requires the various profiles coming out of Master's degrees in Engineering to have hyper-technical specialisation. As a technical university, we are well prepared to provide this specialisation as we design Master's programmes that integrate, recombine and extend the different scientific areas within our second-level training offer. On top of this we also rely on our experience in company applied research and technology."

Politecnico di Torino is recognized as one of the most respected universities in Europe and Reply is a company that has made innovation and technological specialization its flagship. Both entities have joined forces to create a training path for excellence; one aimed at preparing the professionals the industry needs to face the challenges of the future.

More information available at master.reply.com and https://didattica.polito.it/master/ai_cloud/2022/at_a_glance.

°°°

REPLY
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Specializing Master's Programmes and Lifelong Learning School of the Politecnico di Torino
The Specializing Master's Programmes and Lifelong Learning School of the Politecnico di Torino was founded in December 2011 with the aim of organising and managing first-level and second-level Master’s programmes, as well as Lifelong Learning courses, including executive courses. The School stands out for the variety and multidisciplinary nature of its Master’s programmes and training courses, which are an expression of the many scientific and cultural areas present within a research university such as the Politecnico di Torino. The training offer proposed by the School covers several disciplinary areas in order to provide support to companies and public and private institutions, so that they develop their transition ability towards new technological, economic and social paradigms (e.g. electrification, sustainability, digital transformation). Consistent with the polytechnic tradition, the scientific areas underpinning the School's continuing education offer are related to Industry 4.0, new forms of mobility, development and technology transfer in aerospace, digital transformation of businesses, public administration and society, environmental and energy sustainability, digitalisation in construction, new approaches and new frontiers in design, and the design of territories in the perspective of resilience.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

Reply
Fabio Zappelli
f.zappelli@reply.com

Aaron Miani
a.miani@reply.com

Politecnico di Torino
Media Relations
Elena Foglia Franke
relazioni.media@polito.it

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w

Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021

Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 20:46:00 CEST | Press release

Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli

Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 19:01:00 CEST | Press release

The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li

Wipro Announces Co-innovation Space with Google Cloud17.9.2021 15:32:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou

Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 15:00:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu

BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 14:00:00 CEST | Press release

BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom